221,711 Shares in Paysign, Inc. (NASDAQ:PAYS) Bought by Royce & Associates LP

Royce & Associates LP purchased a new stake in Paysign, Inc. (NASDAQ:PAYS - Free Report) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 221,711 shares of the company's stock, valued at approximately $814,000. Royce & Associates LP owned approximately 0.42% of Paysign as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in PAYS. BNP Paribas Financial Markets lifted its position in shares of Paysign by 49.7% in the first quarter. BNP Paribas Financial Markets now owns 39,452 shares of the company's stock valued at $144,000 after buying an additional 13,093 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of Paysign by 3.0% in the first quarter. Vanguard Group Inc. now owns 1,649,043 shares of the company's stock valued at $6,035,000 after buying an additional 48,489 shares during the last quarter. Quadrature Capital Ltd acquired a new stake in shares of Paysign in the first quarter valued at approximately $147,000. Bank of New York Mellon Corp lifted its position in shares of Paysign by 5.2% in the second quarter. Bank of New York Mellon Corp now owns 85,964 shares of the company's stock valued at $371,000 after buying an additional 4,248 shares during the last quarter. Finally, Rhumbline Advisers lifted its position in shares of Paysign by 25.1% in the second quarter. Rhumbline Advisers now owns 35,835 shares of the company's stock valued at $154,000 after buying an additional 7,190 shares during the last quarter. 25.89% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, Barrington Research reissued an "outperform" rating and set a $7.00 price target on shares of Paysign in a report on Monday, November 4th.

Insiders Place Their Bets

In other news, CEO Mark Newcomer sold 50,000 shares of Paysign stock in a transaction on Monday, September 23rd. The stock was sold at an average price of $4.25, for a total value of $212,500.00. Following the transaction, the chief executive officer now owns 9,486,886 shares in the company, valued at approximately $40,319,265.50. This trade represents a 0.52 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, major shareholder Daniel Spence sold 100,000 shares of Paysign stock in a transaction on Friday, September 27th. The shares were sold at an average price of $3.60, for a total value of $360,000.00. Following the completion of the transaction, the insider now owns 9,090,000 shares in the company, valued at approximately $32,724,000. The trade was a 1.09 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 301,360 shares of company stock worth $1,112,036 in the last 90 days. Company insiders own 23.30% of the company's stock.

Paysign Trading Up 2.7 %

NASDAQ:PAYS opened at $3.39 on Thursday. The stock has a 50 day simple moving average of $3.87 and a 200 day simple moving average of $4.30. Paysign, Inc. has a 1-year low of $2.22 and a 1-year high of $5.59. The stock has a market cap of $181.53 million, a P/E ratio of 22.60 and a beta of 0.95.

Paysign (NASDAQ:PAYS - Get Free Report) last posted its quarterly earnings data on Tuesday, November 5th. The company reported $0.03 EPS for the quarter, topping analysts' consensus estimates of $0.01 by $0.02. Paysign had a return on equity of 30.64% and a net margin of 14.28%. The firm had revenue of $15.26 million for the quarter, compared to analyst estimates of $14.96 million. During the same quarter last year, the company earned $0.02 EPS. As a group, sell-side analysts forecast that Paysign, Inc. will post 0.21 EPS for the current year.

Paysign Profile

Paysign, Inc provides prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing services for businesses, consumers, and government institutions. Its product offerings include solutions for corporate rewards, prepaid gift cards, general purpose reloadable debit cards, employee incentives, consumer rebates, donor compensation, clinical trials, healthcare reimbursement payments and pharmaceutical payment assistance, and demand deposit accounts accessible with a debit card.